These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Going After METex14 in NSCLC.
    Journal: Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157.
    Abstract:
    Patients with non-small cell lung cancer harboring MET exon 14 skipping mutations have commonly been treated with the multikinase inhibitor crizotinib, but more MET-specific therapies are being developed. Two such agents, capmatinib and tepotinib, have demonstrated preliminary efficacy in ongoing phase II trials.
    [Abstract] [Full Text] [Related] [New Search]